Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quinolysine
- Development stage
- Phase 1
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quinolysine is a selective alpha-1A adrenergic receptor (α1A-AR) antagonist developed by the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences. It is primarily being investigated for the treatment of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). By selectively blocking the α1A subtype, which is the predominant alpha-adrenergic receptor in the human prostate and bladder neck, quinolysine promotes smooth muscle relaxation to improve urinary flow. This high degree of selectivity is intended to provide therapeutic efficacy while minimizing systemic side effects, such as orthostatic hypotension, which are commonly associated with non-selective alpha-1 adrenergic antagonists.
- Other names
- 喹啉利辛
02
Targets
ADRA1A (α1A)
Beyond the preview
Go deeper on quinolysine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quinolysine.